This page is intended as reference information for the general public.
What is Tygacil and what is it used for ?
Tygacil is an antibiotic medicine of the glycylcycline group that works by stopping the growth of bacteria that cause infections.
Tygacil is used to treat adults or children at least 8 years of age with the following serious infections:
Complicated infection in the abdomen
Complicated infection of the skin or soft tissues (the tissue below the skin), excluding diabetic foot infections.
Medical professionals carefully consider a range of factors before recommending which antibiotic to prescribe. Tygacil is only used when other antibiotics are not considered to be suitable.
Tygacil is given as an intravenous infusion, usually in hospital. It is only available with a prescription.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Tygacil please follow these links:
Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.
If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.